Clinical Trial Goal
To find out:
- The highest dose of TL-895 that's safe to give
- If TL-895 is safe and works well to treat myelofibrosis that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following diseases that has relapsed or is refractory:
- Post-essential thrombocythemia myelofibrosis
- Post-polycythemia vera myelofibrosis
- Primary myelofibrosis
- Have not been treated with any of the following. Your doctor can tell you this:
- BMX inhibitor
- BTK inhibitor
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
TL-895 is a tyrosine kinase inhibitor (TKI) that blocks brutons tyrosine kinase (BTK) in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- TL-895 – A pill that you take by mouth up to 2 times each day
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for about 3.5 years.
The Food and Drug Administration (FDA) has not yet approved TL-895.
Contacts
John Mei, 650-542-0136, jmei@teliospharma.com
Emily Houlihan, 401-954-8042, ehoulihan@teliospharma.com
Locations
Sponsors
lead: Telios Pharma, Inc.
